The frequency and significance of WT-1 expression in serous endometrial carcinoma

• Published in: Human pathology 2014-09, Vol.45 (9), p.1879-1884
• Main Authors: Hedley, Catherine, BSc, Sriraksa, Ruethairat, PhD, Showeil, Rania, MBBCh, Van Noorden, Susan, BSc, El-Bahrawy, Mona, PhD
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antigens; Biomarkers, Tumor - metabolism; Breast cancer; Carcinoma, Endometrioid - metabolism; Carcinoma, Endometrioid - pathology; Cell adhesion & migration; Cohort Studies; Confidence intervals; Cystadenocarcinoma, Serous - metabolism; Cystadenocarcinoma, Serous - pathology; Disease-Free Survival; Endometrial cancer; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Female; Gene Expression Regulation, Neoplastic; Histopathology; Humans; Immunohistochemistry; Immunotherapy; Kaplan-Meier Estimate; Medical prognosis; Metastasis; Middle Aged; Multivariate analysis; Paraffin Embedding; Pathology; Prognosis; Prognostic marker; Serous carcinoma; Studies; Therapeutic target; Tumors; WT-1; WT1 Proteins - metabolism
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2014.05.009

Summary Serous endometrial carcinoma is an aggressive type of endometrial carcinoma. Wilms tumor gene 1 (WT-1) is commonly expressed in ovarian serous carcinomas and considered a diagnostic marker of these tumors. However, it is generally believed that WT-1 is rarely expressed by endometrial serous carcinoma. The aim of this study was to evaluate the frequency and significance of WT-1 expression in endometrial serous carcinoma. We studied the expression of WT-1 in formalin-fixed, paraffin-embedded tumor sections from 77 cases of endometrial serous carcinoma. Thirty-four tumors showed positive expression for WT-1 (44%). There was a statistically significant association between the presence of WT-1 expression and disease-free survival (DFS), where patients with tumors expressing WT-1 had a shorter DFS compared with those with no WT-1 expression ( P = .031; median DFS, 15 and 38 months, respectively). By multivariate Cox regression analysis, DFS was independent from other clinicopathological data (tumor stage, presence of lymphovascular space invasion, cervical involvement, and extrauterine spread), indicating that WT-1 expression is independently associated with DFS. Our study shows that WT-1 is expressed in a considerable percentage of endometrial serous carcinomas, suggesting a role for WT-1 in the pathology of these tumors. This has therapeutic significance, as WT-1 is an emerging target for immunotherapy. Moreover, our results show that WT-1 has prognostic value, being predictive of DFS. As a potential prognostic marker and therapeutic target, we recommend that WT-1 expression should be included in histopathologic reports of endometrial serous carcinoma.